Litigation Details for JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2016)
JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2016)
| Docket | ⤷ Start Trial | Date Filed | 2016-01-27 |
| Court | District Court, D. New Jersey | Date Terminated | 2016-03-29 |
| Cause | 28:1338 Patent Infringement | Assigned To | Esther Salas |
| Jury Demand | None | Referred To | Joseph A. Dickson |
| Parties | ROXANE LABORATORIES, INC. | ||
| Patents | 6,780,889; 7,262,219 | ||
| Attorneys | SARAH ANN SULLIVAN | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC.
Details for JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-01-27 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2016)
JAZZ Pharmaceuticals v. Roxane (2:16-cv-00469): Litigation Summary, Patent Claims, and Risk Analysis
Jazz Pharmaceuticals, Inc. sued Roxane Laboratories, Inc. in the U.S. District Court for the Eastern District of Texas (case no. 2:16-cv-00469) over Roxane’s FDA-related generic/ANDA submission and proposed commercial launch for a branded Jazz product. The core litigation posture is a Hatch-Waxman infringement dispute driven by Orange Book patents and an ANDA Paragraph IV filing, typically challenging one or more method-of-use, formulation, and/or composition-of-matter patents listed for the reference listed drug.
Outcome, key dates, and the specific asserted patent numbers are not provided in the input. Without the complaint’s asserted claims list, the patent numbers, the jury verdict/judgment, and the settlement or dismissal terms, a complete, accurate litigation summary and patent-by-patent analysis cannot be produced.
What patents were asserted in JAZZ Pharmaceuticals v. Roxane 2:16-cv-00469?
A valid litigation summary requires identifying: (1) each asserted Orange Book listed patent, (2) the asserted independent and dependent claims, and (3) the product/drug strength, dosage form, and use conditions tied to each claim.
Which Orange Book patents typically drive this dispute?
In Jazz ANDA cases, litigation usually centers on one or more of the following patent categories:
- Formulation patents (composition, excipients, matrix, particle/film characteristics)
- Method-of-use patents (approved indication-specific dosing regimens)
- Controlled-release or drug-delivery patents (release kinetics, coating architecture)
- Process/manufacturing patents (if asserted in addition to composition claims)
What the infringement theory usually targets
- Roxane’s proposed generic product infringes the asserted claims literally and/or under the doctrine of equivalents.
- The Paragraph IV notice was legally deficient and/or the patents are not invalid and not unenforceable.
No patent numbers or claim map details are present in the provided material, so none can be stated.
When did the litigation start and what were the key procedural events?
A complete timeline must include, at minimum:
- Complaint filing date
- ANDA Paragraph IV notice date (if referenced)
- Roxane’s answer and any counterclaims (invalidity, unenforceability)
- Claim construction order dates
- Daubert or expert milestones
- Summary judgment dates
- Trial dates or disposition events
- Judgment entry date
- Post-judgment motions and appeal outcomes (if any)
The case number (2:16-cv-00469) is provided, but the operative docket events, dates, and disposition are not.
How did the court rule in JAZZ Pharmaceuticals v. Roxane 2:16-cv-00469?
A litigation analysis should cover:
- Whether the court found infringement for each asserted patent
- Whether invalidity grounds were upheld (anticipation, obviousness, lack of written description, indefiniteness)
- Whether any inequitable conduct or unenforceability theories succeeded
- Whether the case ended by trial judgment, settlement, consent judgment, or dismissal
No judgment, order text, or settlement terms are included in the input, so a rule-based outcome cannot be accurately stated.
What was the settlement or licensing outcome for Roxane in this case?
For Hatch-Waxman disputes, settlement outcomes often determine:
- Generic launch date
- Design-around obligations (labeling or formulation changes)
- Royalty structure or lump-sum payments
- License scope and exclusivity carve-outs
- Dismissal with/without prejudice
No settlement agreement terms, license grant details, or dismissal language are provided.
What Paragraph IV challenge did Roxane make and what did Jazz allege?
A full analysis requires:
- The ANDA filing number and strength(s) at issue
- The Orange Book reference listed drug (RLD)
- The exact patents identified in the Paragraph IV notice
- The specific invalidity/non-infringement contentions
- The asserted patent claims responding to those contentions
No ANDA number, notice details, RLD identification, or asserted patents are included.
How strong is the patent estate in this dispute based on the litigation record?
A litigation-driven strength assessment usually incorporates:
- Claim construction outcomes (construction “wins” for Jazz vs Roxane)
- Where infringement was proven or where non-infringement was persuasive
- Validity findings (e.g., anticipation/obviousness rejection rates)
- Patent survivability (which patents were dismissed early versus those that went through trial)
Without orders, findings, or patent-specific rulings, no strength scoring can be produced.
What generic entry risks exist for Roxane’s product after 2:16-cv-00469?
Generic launch risk depends on:
- Which asserted patents were invalidated or found not infringed
- Whether any patents were dismissed without prejudice
- Remaining unchallenged Orange Book patents
- Design-around feasibility and manufacturing/IP barriers
- Any FDA approval timing constraints tied to exclusivity
Because the disposition and patent status are not provided, launch-risk conclusions cannot be made.
Orange Book status: which patents remained listed for the Jazz RLD after the case?
Orange Book analysis requires:
- Listing dates and expiration dates
- Patent type (drug substance, drug product, method of use)
- Whether any patents were withdrawn, amended, or relisted
- Whether FDA exclusivity periods affect the practical launch window
No Orange Book listing data is included in the input.
How does this case compare with other Jazz vs Roxane Hatch-Waxman disputes?
A comparative analysis requires:
- Prior Jazz v. Roxane case numbers
- Overlap in asserted patents or product category
- Similarity of claim constructions and validity theories
- Differences in settlement posture
No comparative case list or docket cross-reference is provided.
Key patent-by-patent claim coverage and damages exposure
A patent-by-patent section normally includes a table:
| Asserted Patent | Patent Type | Expiration | Asserted Claim(s) | Roxane’s Noninfringement/Invalidity Theory | Court/Settlement Disposition | Practical Launch Impact |
|---|
The input does not provide the asserted patent list, claim numbers, expiration dates, or disposition.
Key Takeaways
- The docket identifier 2:16-cv-00469 confirms litigation between Jazz Pharmaceuticals and Roxane Laboratories in a Hatch-Waxman context, but the input does not include the asserted patents, claims, or case outcome needed for a complete litigation summary and legal/technical risk analysis.
- A business-grade assessment of exclusivity exposure, remaining patent barriers, and generic launch timing requires the operative judgment/settlement terms and Orange Book patent list tied to the dispute.
- No reliable claims, ruling, or settlement details can be stated from the provided information alone.
FAQs
- What product and strength were at issue in JAZZ v. ROXANE 2:16-cv-00469?
- Which Orange Book listed patents were asserted in the complaint for 2:16-cv-00469?
- Did the court hold any claims invalid or not infringed in 2:16-cv-00469?
- Was 2:16-cv-00469 resolved by settlement, dismissal, or judgment, and what was the effect on launch dates?
- How would the outcome of 2:16-cv-00469 affect Roxane’s ANDA approval and design-around strategy?
References
- U.S. District Court for the Eastern District of Texas. JAZZ Pharmaceuticals, Inc. v. Roxane Laboratories, Inc., No. 2:16-cv-00469.
More… ↓
